Studies have shown an association of increased serum levels of IGF-I and decreased levels of IGFBP-3 with an increased risk of breast cancer in premenopausal women [13,14], suggesting that these patients may benefit from measures able to reduce serum IGF-I levels and increase IGFBP-3 levels. The gene discussed is IGFBP3; the disease is breast carcinoma.